Viridian Therapeutics Net Worth
Viridian Therapeutics Net Worth Breakdown | VRDN |
Viridian Therapeutics Net Worth Analysis
Viridian Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Viridian Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Viridian Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Viridian Therapeutics' net worth analysis. One common approach is to calculate Viridian Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Viridian Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Viridian Therapeutics' net worth. This approach calculates the present value of Viridian Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Viridian Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Viridian Therapeutics' net worth. This involves comparing Viridian Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Viridian Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Viridian Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Viridian Therapeutics' net worth research are outlined below:
| Viridian Therapeutics generated a negative expected return over the last 90 days | |
| Viridian Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (237.95 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (232.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Viridian Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 |
Viridian Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Viridian Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Viridian Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Viridian Therapeutics Target Price Consensus
Viridian target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Viridian Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 17 | Strong Buy |
Most Viridian analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Viridian stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Viridian Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationViridian Therapeutics Target Price Projection
Viridian Therapeutics' current and average target prices are 15.26 and 40.44, respectively. The current price of Viridian Therapeutics is the price at which Viridian Therapeutics is currently trading. On the other hand, Viridian Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Viridian Therapeutics Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Viridian Therapeutics Target Price
Know Viridian Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Viridian Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viridian Therapeutics backward and forwards among themselves. Viridian Therapeutics' institutional investor refers to the entity that pools money to purchase Viridian Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Novo A/s | 2024-12-31 | 2.2 M | Maverick Capital Ltd | 2024-12-31 | 2.1 M | Driehaus Capital Management Llc | 2024-12-31 | 1.9 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 1.8 M | Adage Capital Partners Gp Llc | 2024-12-31 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.7 M | Perceptive Advisors Llc | 2024-12-31 | 1.5 M | Loomis, Sayles & Company Lp | 2024-12-31 | 1.4 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 11.9 M | Blackrock Inc | 2024-12-31 | 5.8 M |
Follow Viridian Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.25 B.Market Cap |
|
Project Viridian Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.40) | (0.38) |
When accessing Viridian Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Viridian Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Viridian Therapeutics' profitability and make more informed investment decisions.
Evaluate Viridian Therapeutics' management efficiency
Viridian Therapeutics has return on total asset (ROA) of (0.3032) % which means that it has lost $0.3032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4848) %, meaning that it created substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Viridian Therapeutics' Total Assets are very stable compared to the past year. As of the 22nd of March 2025, Non Currrent Assets Other is likely to grow to about 972.3 K, while Non Current Assets Total are likely to drop about 2.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.89 | 6.11 | |
| Tangible Book Value Per Share | 9.89 | 6.11 | |
| Enterprise Value Over EBITDA | (4.59) | (4.82) | |
| Price Book Value Ratio | 1.94 | 3.81 | |
| Enterprise Value Multiple | (4.59) | (4.82) | |
| Price Fair Value | 1.94 | 3.81 | |
| Enterprise Value | 1.2 B | 1.3 B |
Management at Viridian Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viridian Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viridian Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viridian Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viridian Therapeutics Corporate Filings
F3 | 12th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 3rd of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Viridian Therapeutics Earnings per Share Projection vs Actual
Viridian Therapeutics Corporate Management
| Seth Harmon | Principal Accounting | Profile | |
| Anthony Casicano | Chief Officer | Profile | |
| Kristian MBA | Chief CFO | Profile | |
| Melissa Manno | Chief Officer | Profile | |
| Anthony Casciano | Chief Officer | Profile | |
| Jennifer JD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.